EGFR and colorectal cancer: In this study, we show that we can control ERBB2 across a wide range of cancers, namely, NCI-H1975 ERBB2-expressing osimertinib-resistant EGFR T790M non-small-cell lung cancer, wildtype ERBB2+ breast cancer BT474, BT474 clone 5 ERBB2+ trastuzumab-resistant breast cancer, NCI-H2030 ERBB2-mutated non-small-cell lung cancer, and ERBB2-expressing HCT116 colorectal cancer.